SCHEMBL4010818

SCHEMBL4010818

O=C(N[C@H]1CCCN(S(=O)(=O)c2cc(Cl)ccc2F)C1)C1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
HSD11B1 P28845 1/20 0.58
EPHX2 P34913 8/20 0.58
KMT2A Q03164 2/20 0.56
POLB P06746 2/20 0.54
RAB9A P51151 1/20 0.54
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010823 1.00 KDM4E (0.60) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL610353 0.95 HSD11B1 (0.65) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL612160 0.95 HSD11B1 (0.65) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL4005137 0.92 ALDH1A1 (0.72) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL610672 0.87 KDM4E (0.59) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL610671 0.87 KDM4E (0.59) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL4960307 0.86 KDM4E (0.53) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL610748 0.86 KDM4E (0.53) KDM4EALDH1A1HSD11B1EPHX2KMT2A
SCHEMBL4143730 0.86 EPHX2 (0.78) ALDH1A1HSD11B1EPHX2KMT2APOLB
SCHEMBL4005534 0.84 RAB9A (0.70) ALDH1A1HSD11B1EPHX2KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 KDM4E 3505/4885ALDH1A1 311/4885HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.